PX'Therapeutics Announces EuroNeut-41 Prophylactic HIV Vaccine Clinical Trial

PX'Therapeutics Announces EuroNeut-41 Prophylactic HIV Vaccine Clinical Trial

GRENOBLE, France, Mar 12, 2012 (BUSINESS WIRE) -- PX'Therapeutics is pleased to announce the launching of a Phase 1 clinical trial of a prophylactic vaccine against HIV entitled: "Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers."

Funded under the European Union's Seventh Research Framework Programme (FP7), the collaborative project EuroNeut-41 aims at developing new vaccines able to elicit neutralizing antibodies that block entry of HIV into cells at mucosal sites and in blood. These vaccine candidates are derived from the envelope of HIV. The gp41 transmembrane envelope protein plays a key role in virus entry and displays regions that are well preserved among sub-types. It is expected that antibodies directed against this protein will provide sterilizing immunity against a broad range of HIV sub-type viruses.

The EuroNeut-41 project involves 17 partners, including Sanofi Pasteur (Marcy l'Etoile, France) as the coordinator of the project, the University of Granada (Granada, Spain) for the design of the constructs, Polymun Scientific (Vienna, Austria) for the formulation of the product, Clinical Research Centre, University of Surrey (Guildford, United Kingdom) as the Principal Investigator, and PX'Therapeutics (Grenoble, France) for the process development, GMP manufacturing of the protein along with the sponsorship of the trial.

More information on http://www.euroneut-41.eu/

About PX'Therapeutics

PX'Therapeutics, located in Grenoble and Lyon (France), offers early stage research and GMP manufacturing services focusing on the development of therapeutic proteins, monoclonal antibodies and recombinant vaccines. PX'Therapeutics designs custom programs targeting development of monoclonal antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development and GMP manufacturing.

More information on www.px-therapeutics.com

SOURCE: PX'Therapeutics

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.